Geoffrey R. Oxnard, MD

Articles by Geoffrey R. Oxnard, MD

42 Tissue and Liquid Biopsy–Based Comprehensive Genomic Profiling Reveal Mechanisms of Therapy Resistance and Rare Targetable Alterations in Breast Cancer

ByEthan Sokol,Smruthy Sivakumar,Dexter X. Jin,Hanna Tukachinsky,Karthikeyan Murugesan,Dean Pavlick,Jeffrey S. Ross, MD,Garrett M. Frampton,Geoffrey R. Oxnard, MD,Priti S. Hegde

April 18th 2022

Use of Erlotinib or Gefitinib as Initial Therapy in Advanced NSCLC

ByGeoffrey R. Oxnard, MD,Vincent A. Miller, MD

April 30th 2010

Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR), such as erlotinib (Tarceva) and gefitinib (Iressa), have shown remarkable activity in a portion of patients with non–small-cell lung cancer (NSCLC).

Latest Updated Articles

Use of Erlotinib or Gefitinib as Initial Therapy in Advanced NSCLC
April 30th 2010

Geoffrey R. Oxnard, MD

Articles by Geoffrey R. Oxnard, MD

42 Tissue and Liquid Biopsy–Based Comprehensive Genomic Profiling Reveal Mechanisms of Therapy Resistance and Rare Targetable Alterations in Breast Cancer

Use of Erlotinib or Gefitinib as Initial Therapy in Advanced NSCLC

Latest Updated Articles

Trending on CancerNetwork

One of “The Best Opportunities” for Long-Term Remission in Multiple Myeloma

Blood-Based Lung Cancer Screening Tool Earns FDA Breakthrough Device Status

What Does Priority Review Mean for Subcutaneous Amivantamab in HNSCC?

What Are The Biggest Misconceptions About CAR T Cells in Multiple Myeloma?

How AI and Health Networks Are Democratizing Clinical Trial Access